Article

Case Study of a 33-Year-Old With Metastatic Colorectal Cancer

Author(s):

In this segment, David Liu, shares a case study of a 33-year-old woman with stage 4 colorectal cancer that had metastasized to the liver.

In this segment, David Liu, shares a case study of a 33-year-old woman with stage 4 colorectal cancer that had metastasized to the liver. The patient presented to Liu's practice with the primary tumor intact and bowel obstruction. Following resection of the primary tumor, systemic therapy was initiated with cetuximab plus FOLFOX chemotherapy for two months before toxicity was encountered. At this time, it was discovered that the patient had a KRAS mutation, which limited her subsequent therapeutic options.

Upon review by a tumor board, the decision was made to treat her with liver-directed SIR-Spheres (Yttrium-90-resin microspheres) off protocol. Liu and his colleagues made this decision after a careful consideration of the patient’s presentation of disease, nonresponse and intolerance to previous systemic therapy, KRAS-mutant status and her estimated survival of approximately one year.

After her selective internal radiation therapy (SIRT) procedure, the liver was not a consideration anymore, since subsequent scans continued to show a lack of liver lesions, says Liu. By treating the liver, the patients had an improved chance of living longer. The patient later developed ovarian drop metastases (Krukenberg tumor), which was surgically resected. She also developed pulmonary lesions, which were effectively treated with a combination of ablation and surgical resection. In the end, she developed brain metastases.

The patient survived 54 months, which is significantly longer than the 12-month anticipation, according to Liu.

Related Videos
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Dr. Richard “Rick" Winneker
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with brown and grey hair.
Image of man with grey hair.
Image of bald man in suit.
Related Content